1. Kabins D, Gershon S. Potential applications for monoamine oxidase inhibitors. Dementia 1990; 1: 323–348.
2. Riederer P, Youdim MBH, Rausch WD. On the mode of action of l-deprenyl in the human nervous system. J Neural Transm 1978; 43: 217–226.
3. Finberg JPM. Effects of selective inhibition of MAO types A and B on peripheral symphatetic function. In: Kamijo K, Usdin E, Nagatsu, editors. Monoamine oxidase: Basic and clinical frontiers. Princeton: Excerpta Medica 1982, 174–182.
4. Green AR, Mitchell BD, Tordoff A, Youdim MBH. Evidence for dopamine deamina-tion by both type A and B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmac 1977; 60: 343.
5. Demarest KT, Smith DJ, Azzaro AJ. The presence of type A form of monoamine oxidase within nigrostriatal dopamine containing neurons. J Pharmac Exp Ther 1980; 215:461–468.